» Articles » PMID: 28470113

Nebulized Drug Delivery in Respiratory Medicine: What Does the Future Hold?

Overview
Journal Ther Deliv
Date 2017 May 5
PMID 28470113
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

In the later half of the 20th century, nebulized therapy was in decline, but in the 21st century the prospects for the expanded use of nebulized therapy within respiratory medicine look bright. The advent of mesh nebulizers, which combine the universal applicability of the nebulizer in the treatment of all respiratory patients with the convenience of portable inhaler use, is ideally timed to capitalize on the forecast of increased numbers of patients who will require nebulized therapy in the future. This special report will highlight some of the opportunities that the development of mesh nebulizers presents in the field of respiratory medicine.

Citing Articles

Towards More Precise Targeting of Inhaled Aerosols to Different Areas of the Respiratory System.

Sosnowski T Pharmaceutics. 2024; 16(1).

PMID: 38258107 PMC: 10818612. DOI: 10.3390/pharmaceutics16010097.


Evaluation of Aerosol Therapy during the Escalation of Care in a Model of Adult Cystic Fibrosis.

Fernandez Fernandez E, Joyce M, OSullivan A, MacLoughlin R Antibiotics (Basel). 2021; 10(5).

PMID: 33919035 PMC: 8142975. DOI: 10.3390/antibiotics10050472.


Revefenacin, a once-daily, long-acting muscarinic antagonist, for nebulized maintenance therapy in patients with chronic obstructive pulmonary disease.

Hvisdas C Am J Health Syst Pharm. 2021; 78(13):1184-1194.

PMID: 33821890 PMC: 8083528. DOI: 10.1093/ajhp/zxab154.


Aerosol Characteristics and Physico-Chemical Compatibility of Combivent (Containing Salbutamol and Ipratropium Bromide) Mixed with Three Other Inhalants: Budesonide, Beclomethasone or N-Acetylcysteine.

Zhang R, Hu J, Deng L, Li S, Chen X, Liu F Pharmaceutics. 2020; 12(1).

PMID: 31963493 PMC: 7023084. DOI: 10.3390/pharmaceutics12010078.


Improvements in Lung Function with Nebulized Revefenacin in the Treatment of Patients with Moderate to Very Severe COPD: Results from Two Replicate Phase III Clinical Trials.

Ferguson G, Feldman G, Pudi K, Barnes C, Moran E, Haumann B Chronic Obstr Pulm Dis. 2019; 6(2):154-165.

PMID: 30974049 PMC: 6596436. DOI: 10.15326/jcopdf.6.2.2018.0152.